Gouvernance Ligand Pharmaceuticals Incorporated

LGND

US53220K5048

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 05/08/2026			Varia. 5j.	Varia. 1 janv.
302,57 ^USD	+0,59%		+2,12%	+60,03%

09:30	Ligand Pharmaceuticals : un dirigeant cède pour 1 444 951 $ d'actions, selon un document de la SEC	MT
03/08	LIGAND PHARMACEUTICALS INCORPORATED : Oppenheimer toujours positif	ZM

Comité Exécutif: Ligand Pharmaceuticals Incorporated

Dirigeant

Fonctions occupéesDepuis

Todd Davis

66 ans

Chief Executive Officer

05/12/2022

Melanie Herman

47 ans

Investor Relations Contact

Paul J. Hadden

Chief Investment Officer

Vincent Antle

57 ans

Chief Tech/Sci/R&D Officer

01/01/2011

Andrew Reardon

52 ans

General Counsel	01/01/2022
Corporate Secretary	01/01/2022

Octavio Espinoza

56 ans

Director of Finance/CFO

01/11/2022

Composition du Conseil d'Administration: Ligand Pharmaceuticals Incorporated

Administrateur

ComitésDepuis

John Kozarich

76 ans

Governance Committee	01/03/2003
Nominating Committee	01/03/2003

Jason Aryeh

57 ans

Compensation Committee	26/01/2023
HR Committee
Governance Committee Chair	26/01/2023
Nominating Committee Chair	26/01/2023
Audit Committee Chair
Audit Committee	01/08/2024
Governance Committee	01/08/2024
Nominating Committee	01/08/2024

John LaMattina

76 ans

Compensation Committee	14/05/2012
HR Committee
Audit Committee	13/06/2023
Compensation Committee Chair	01/01/2009

Todd Davis

66 ans

Compensation Committee Chair	13/12/2024
Governance Committee	13/12/2024
Nominating Committee	13/12/2024

Nancy Gray

66 ans

Audit Committee
Governance Committee
Nominating Committee

Jason Haas

58 ans

Audit Committee	29/06/2022
Compensation Committee Chair
HR Committee Chair

Stephen Sabba

66 ans

Audit Committee Chair

30/11/2011

Martine Zimmermann

57 ans

Audit Committee

26/09/2023

Dernières Nominations: Ligand Pharmaceuticals Incorporated

02/07/25	Pelthos Therapeutics Inc. annonce des changements à la direction générale, effectifs au 1er juillet 2025	CI
17/04/25	Pelthos Therapeutics, filiale de Ligand, va fusionner avec Channel Therapeutics	RE
05/08/24	Matthew Korenberg, directeur de l'exploitation de Ligand Pharmaceuticals, quitte l'entreprise	MT
02/08/24	Ligand Pharmaceuticals Incorporated annonce le départ de Matthew Korenberg en tant que président et chef des opérations, à compter du 31 octobre 2024	CI
03/04/24	Ligand Pharmaceuticals nomme Scott Plesha au poste de directeur général	CI
16/02/24	Ligand Pharmaceuticals Incorporated annonce des nominations au sein de sa direction	CI
27/09/23	Ligand Pharmaceuticals Incorporated nomme Martine Zimmermann à son conseil d'administration	CI

Plus d'Actualités

Anciens Dirigeants et Administrateurs: Ligand Pharmaceuticals Incorporated

Insider

Fonctions occupées

DepuisJusqu'au

Audrey Warfield-Graham

Human Resources Officer

01/12/1994

01/03/2024

John Higgins

Director/Board Member	12/07/2011	31/12/2022
Chief Executive Officer	15/01/2007	05/12/2022
President	15/01/2007	27/01/2015

Charles Berkman

General Counsel	01/11/2001	01/11/2022
Corporate Secretary	01/03/2007	01/11/2022

Matthew Foehr

Chief Operating Officer	18/04/2011	01/01/2022
President	27/01/2015	01/01/2022

Nishan de Silva

Director of Finance/CFO	28/02/2014	21/05/2015
Corporate Officer/Principal	07/02/2012	28/02/2014

John Sharp

Director of Finance/CFO

30/04/2007

28/02/2014

Syed M. J. Kazmi

Corporate Officer/Principal

01/01/1995

31/08/2012

Sunil Patel

Director/Board Member	08/10/2010	-
Independent Dir/Board Member	30/11/2011	-

Martin D. Meglasson

Corporate Officer/Principal

01/02/2004

23/07/2010

Steven J. Burakoff

Director/Board Member

01/12/2008

01/01/2010

Bruce Peacock

Director/Board Member

01/12/2008

29/05/2009

Jeffrey R. Perry

Director/Board Member

08/12/2005

20/01/2009

Zofia E. Dziewanowska

Chief Tech/Sci/R&D Officer

01/04/2002

01/01/2009

Elizabeth M. Greetham

Director/Board Member

01/03/2007

29/07/2008

Tod G. Mertes

Comptroller/Controller/Auditor

01/05/2001

15/05/2007

Michael Rocca

Director/Board Member

01/01/2006

Alexander Cross

Director/Board Member

17/03/2007

Carl C. Peck

Director/Board Member

01/01/1997

01/03/2007

Irving S. Johnson

Director/Board Member

01/01/1989

01/03/2007

John Groom George

Director/Board Member

01/01/1995

01/03/2007

Daniel Loeb

Director/Board Member

01/12/2005

28/02/2007

Brigette Roberts

Director/Board Member

08/12/2005

01/03/2007

David Knott

Director/Board Member	01/03/2007	-
Independent Dir/Board Member	30/11/2011	-

Warner R. Broaddus

General Counsel	01/01/2001	28/02/2007
Corporate Secretary	01/01/2001	28/02/2007

Andres F. Negro-Vilar

Chief Tech/Sci/R&D Officer

01/09/1996

15/02/2007

Taylor Crouch

Corporate Officer/Principal

01/05/2005

01/01/2007

James J. L'Italien

General Counsel

01/01/2002

01/01/2007

Paul Maier

Director of Finance/CFO

01/10/1992

01/01/2007

Richard Ghalie

Chief Tech/Sci/R&D Officer

01/01/2003

01/01/2007

Keith E. Anderson

Corporate Officer/Principal

01/05/2000

01/01/2007

David Eric Robinson

Chairman	-	31/07/2006
President	-	31/07/2006

Maria Bedoya-Toro Munera

General Counsel

01/01/2003

01/01/2006

Mark E. Erwin

Sales & Marketing

01/10/2003

01/06/2005

Jessica Stone Rampton

Corporate Officer/Principal

01/01/2004

Thomas H. Silberg

Chief Operating Officer

01/01/2000

01/05/2003

David C. Furlano

General Counsel

02/01/2002

Richard C. Yocum

Chief Tech/Sci/R&D Officer

01/01/1995

01/01/2002

George M. Stuart

Comptroller/Controller/Auditor

01/05/1999

01/04/2001

Russell L. Allen

Corporate Officer/Principal

01/01/2001

Peter Lamb

Corporate Officer/Principal

01/06/1992

01/09/2000

William Larry Respess

General Counsel

01/01/1988

01/01/2000

Eric S. Groves

Corporate Officer/Principal

01/08/1999

Gregg Stetsko

Corporate Officer/Principal

01/01/1994

01/01/1999

Louis J. Scotti

Corporate Officer/Principal

01/04/1996

01/06/1998

William A. Pettit

Chief Administrative Officer	01/11/1996	-
Human Resources Officer	01/11/1996	-

Robert Stein

Chief Tech/Sci/R&D Officer

01/01/1990

01/01/1996

George F. Horner

Corporate Officer/Principal

01/01/1993

01/01/1995

Tina Nova

Corporate Officer/Principal

01/01/1988

01/01/1992

Rick White

Sales & Marketing

Erika Luib-De la Cruz

Public Communications Contact

Brook Byers

Chairman	-	-
President	-	-

Rob McKay

Investor Relations Contact	19/04/2011	-
Public Communications Contact	26/08/2011	-

Jo Cato

Corporate Officer/Principal

Doug Kelly

Corporate Officer/Principal

Terry A. Dembitz

Chief Administrative Officer

Henry F. Blissenbach

Director/Board Member

Richard Heyman

Chief Tech/Sci/R&D Officer	30/11/2011	-
Corporate Officer/Principal	-	30/11/2011

Becki Filice

Corporate Officer/Principal

Michael J. Weickert

Corporate Officer/Principal

John Wayne Cowens

Corporate Officer/Principal

Giambattista Aliprandi

Chief Tech/Sci/R&D Officer

Robert Tressler

Corporate Officer/Principal

Todd Jones

Corporate Officer/Principal

Howard T. Holden

Compliance Officer	-	-
General Counsel	-	-

Dennis W. Genge

Comptroller/Controller/Auditor	-	-
Director of Finance/CFO	-	-

Drew Senyei

Director/Board Member

Shi-Chung Ng

Corporate Officer/Principal

Erika Luib

Public Communications Contact

Marcus F. Boehm

Corporate Officer/Principal

Ronald J. Christopher

Chief Tech/Sci/R&D Officer	-	-
Corporate Officer/Principal	-	-

Nadine Knowles

Corporate Officer/Principal

Gary R. Eldridge

Corporate Officer/Principal

Rajni Aneja

Corporate Officer/Principal

Howard Birndorf

Director/Board Member	-	-
Founder	-	-

Jaber G. Qasem

Corporate Officer/Principal

Barbara K. Sosnowski

Chief Tech/Sci/R&D Officer

Angeline K. Shashlo

General Counsel

Thomas Jurgensen

General Counsel

Edgar H. Ulm

Director/Board Member

Alex M. Nadzan

Corporate Officer/Principal

Mark Brian Anderson

Chief Tech/Sci/R&D Officer

Curt Bradshaw

Corporate Officer/Principal

Jennifer Capuzelo

Investor Relations Contact	-	-
Public Communications Contact	-	-

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	17
Femme	2

Dont comité exécutif

Homme	5
Femme	1

Dont Administrateurs

Homme	8
Femme	0

Révisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Non

Controverses sur les droits de l'Homme

Non

Controverses Subventions fiscales

Non

Conforme à la finance Islamique

Ligand Pharmaceuticals Incorporated est une société biopharmaceutique qui favorise le progrès scientifique en soutenant le développement clinique de médicaments. Elle y parvient par le biais de financements, de l’octroi de licences sur ses technologies, ou les deux. Elle exploite deux plateformes technologiques de propriété intellectuelle génératrices de redevances et nécessitant peu d’infrastructures. Sa plateforme Captisol est une cyclodextrine chimiquement modifiée dont la structure est conçue pour optimiser la solubilité et la stabilité des médicaments. Cette technologie a permis la mise au point de produits approuvés par la FDA, notamment le Veklury de Gilead, le Kyprolis d’Amgen, le Nexterone de Baxter et l’Evomela d’Acrotech Biopharma. Sa plateforme technologique NITRICIL facilite l’ajustement des posologies, en permettant un profil de libération du médicament modulable afin de créer des formulations exclusives ciblant un large éventail d’indications. Ses technologies comprennent également HepDirect, LTP et Pelican Expression Technology. Elle a conclu de multiples alliances, accords de licence et autres relations commerciales avec diverses sociétés pharmaceutiques.

Employés

Secteur

Produits pharmaceutiques

Agenda

06/08 Publication des résultats - Q2 2026

Plus d'informations sur la société